ECO 2026: tirzepatide shows potential for T1D treatment

Pharmaceutical Technology

During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).

pharminent May 15, 2026

Pharmaceutical Technology

During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).

Related Stories